Walgreens Boots Alliance (NASDAQ:WBA) had its target price cut by Pivotal Research from $73.00 to $69.00 in a report issued on Friday morning. They currently have a hold rating on the pharmacy operator’s stock.
A number of other research firms have also commented on WBA. Bank of America initiated coverage on shares of Walgreens Boots Alliance in a research report on Tuesday, February 27th. They set a neutral rating and a $76.00 price target for the company. Deutsche Bank initiated coverage on shares of Walgreens Boots Alliance in a research report on Monday, December 4th. They set a hold rating and a $78.00 price target for the company. Zacks Investment Research upgraded shares of Walgreens Boots Alliance from a hold rating to a buy rating and set a $76.00 price target for the company in a research report on Wednesday, February 14th. BidaskClub lowered shares of Walgreens Boots Alliance from a sell rating to a strong sell rating in a research report on Thursday. Finally, ValuEngine upgraded shares of Walgreens Boots Alliance from a hold rating to a buy rating in a research report on Thursday, January 4th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of Buy and a consensus target price of $84.45.
Walgreens Boots Alliance (NASDAQ WBA) traded down $0.40 on Friday, hitting $65.43. 6,119,516 shares of the stock were exchanged, compared to its average volume of 5,275,343. The stock has a market cap of $65,215.74, a price-to-earnings ratio of 18.07, a P/E/G ratio of 1.09 and a beta of 1.21. The company has a debt-to-equity ratio of 0.48, a current ratio of 0.96 and a quick ratio of 0.47. Walgreens Boots Alliance has a 12-month low of $63.82 and a 12-month high of $87.79.
Walgreens Boots Alliance (NASDAQ:WBA) last released its quarterly earnings results on Thursday, January 4th. The pharmacy operator reported $1.28 EPS for the quarter, beating analysts’ consensus estimates of $1.27 by $0.01. The firm had revenue of $30.74 billion during the quarter, compared to analyst estimates of $30.39 billion. Walgreens Boots Alliance had a net margin of 3.19% and a return on equity of 19.15%. The business’s revenue for the quarter was up 7.9% on a year-over-year basis. During the same period in the previous year, the business earned $1.10 EPS. research analysts forecast that Walgreens Boots Alliance will post 5.79 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which was paid on Monday, March 12th. Shareholders of record on Thursday, February 15th were paid a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 2.45%. The ex-dividend date was Wednesday, February 14th. Walgreens Boots Alliance’s dividend payout ratio is presently 44.20%.
In other Walgreens Boots Alliance news, insider Stefano Pessina purchased 98,858 shares of the stock in a transaction on Monday, January 15th. The stock was acquired at an average cost of $76.07 per share, with a total value of $7,520,128.06. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 14.80% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the business. Cambridge Investment Research Advisors Inc. lifted its stake in Walgreens Boots Alliance by 17.2% in the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 116,893 shares of the pharmacy operator’s stock worth $8,489,000 after purchasing an additional 17,145 shares during the last quarter. Xact Kapitalforvaltning AB raised its stake in shares of Walgreens Boots Alliance by 5.9% during the fourth quarter. Xact Kapitalforvaltning AB now owns 177,533 shares of the pharmacy operator’s stock valued at $12,892,000 after acquiring an additional 9,960 shares during the last quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp raised its stake in shares of Walgreens Boots Alliance by 63.3% during the fourth quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 740,953 shares of the pharmacy operator’s stock valued at $53,808,000 after acquiring an additional 287,243 shares during the last quarter. Sawtooth Solutions LLC bought a new position in shares of Walgreens Boots Alliance during the fourth quarter valued at about $376,000. Finally, We Are One Seven LLC bought a new position in shares of Walgreens Boots Alliance during the fourth quarter valued at about $869,000. 60.93% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Walgreens Boots Alliance (WBA) Price Target Cut to $69.00 by Analysts at Pivotal Research” was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://ledgergazette.com/2018/03/24/walgreens-boots-alliance-wba-price-target-cut-to-69-00-by-analysts-at-pivotal-research.html.
Walgreens Boots Alliance Company Profile
Walgreens Boots Alliance, Inc (Walgreens Boots Alliance) is a holding company. The Company is a global pharmacy-led, health and wellbeing enterprise. Walgreens Boots Alliance operates through three divisions, including Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale. The Company’s products are marketed under a number of brands, which include No7, the Botanics range, Almus (generic medicines), Boots Pharmaceuticals and Soap & Glory (bathing and beauty brand).
Receive News & Ratings for Walgreens Boots Alliance Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Walgreens Boots Alliance and related companies with MarketBeat.com's FREE daily email newsletter.